RE:RE:We're starting to get part of it...Sorry, cmonreally, there was no financial information because it was likely a material transfer agreement (MTA) as JNJ/Janssen's Macdonald
discussed in the Sachs Associates Alzheiner's panel. If there was no financial aspect to the agreement then the financial media would have no interest, unless, I suppose, the stock starts to run with this name association and the validation of such a low-value company by the world's largest pharma. You know, who knows?
I say both biotech and financial media reports are required and I chose to discuss it in that way for good reasons.
You, on the other hand, cmon, never let facts get in the way of your trolling.
About money, there are too many pharma and biotech collaborators, known and unknown, with interests in the viabiulity of Bioasis for this to go south. Between that and the remaining space within the Lind Partners agreement there's this little itty-bitty chance that Bioasis might, just might, maybe, survive past May.
jd